WAVE LIFE SCIENCES LTD. Cash and Cash Equivalents, Period Increase (Decrease)
WAVE LIFE SCIENCES LTD. (WVE) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$7.79 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-12
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$25.96M.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$28.93M.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $67.91M, a 139.39% increase year-over-year.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$20.81M.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$7.79M.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$10.93M, a 106.82% decline from fiscal 2015.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $160.17M, a 26200.82% increase from fiscal 2014.
- WAVE LIFE SCIENCES LTD. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $609.00K, a 915.00% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$25.96M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$54.89M derived: sum of 2 quarters · filed 2018-03-12 | $13.02M derived: sum of 3 quarters · filed 2018-03-12 | -$7.79M 10-K · filed 2018-03-12 |
| 2017-09-30 | -$28.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $38.98M derived: sum of 2 quarters · filed 2017-11-09 | $18.17M 10-Q · filed 2017-11-09 | -$551.00K derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-06-30 | $67.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $47.10M 10-Q · filed 2017-08-09 | $28.38M derived: sum of 3 quarters · filed 2018-03-12 | $15.63M derived: sum of 4 quarters · filed 2018-03-12 |
| 2017-03-31 | -$20.81M 10-Q · filed 2017-05-10 | -$39.53M derived: sum of 2 quarters · filed 2018-03-12 | -$52.28M derived: sum of 3 quarters · filed 2018-03-12 | -$23.91M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-12-31 | -$18.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$31.47M derived: sum of 2 quarters · filed 2018-03-12 | -$3.10M derived: sum of 3 quarters · filed 2018-03-12 | -$10.93M 10-K · filed 2018-03-12 |
| 2016-09-30 | -$12.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $15.62M derived: sum of 2 quarters · filed 2017-11-09 | $7.79M 10-Q · filed 2017-11-09 | $102.97M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $28.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $20.55M 10-Q · filed 2017-08-09 | $115.72M derived: sum of 3 quarters · filed 2018-03-12 | $173.99M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-03-31 | -$7.82M 10-Q · filed 2017-05-10 | $87.36M derived: sum of 2 quarters · filed 2018-03-12 | $145.62M derived: sum of 3 quarters · filed 2018-03-12 | $142.44M derived: sum of 4 quarters · filed 2018-03-12 |
| 2015-12-31 | $95.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $153.44M derived: sum of 2 quarters · filed 2018-03-12 | $150.26M derived: sum of 3 quarters · filed 2018-03-12 | $160.17M 10-K · filed 2018-03-12 |
| 2015-09-30 | $58.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $55.08M derived: sum of 2 quarters · filed 2016-11-09 | $64.99M 10-Q · filed 2016-11-09 | $63.55M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $6.73M 10-Q · filed 2016-08-15 | $5.29M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2015-03-31 | $9.91M 10-Q · filed 2016-05-16 | $8.47M derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2014-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $609.00K 10-K · filed 2017-03-16 | ||
| 2014-09-30 | $2.05M 10-Q · filed 2015-12-17 | |||
| 2013-12-31 | $60.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |